Upload
advanced-cell-technology-inc
View
129
Download
3
Tags:
Embed Size (px)
DESCRIPTION
8/10/2005
Citation preview
The promise of human embryonic stem cell therapies
Robert Lanza, MD
VP Medical & Scientific Development
Advanced Cell Technology
and Adjunct Professor
Wake Forest University School of Medicine
CAUTIONARY STATEMENTCONCERNING FORWARD-LOOKING STATEMENTS
This presentation contains “forward-looking statements” as defined under the federal securities laws. Actual results could vary materially. Factors that could cause actual results to vary materially are described in our filings with the Securities and Exchange Commission. You should pay particular attention to the “risk factors” contained in documents we file from time to time with the Securities and Exchange Commission. The risks identified therein, as well as others not identified by the Company, could cause the Company’s actual results to differ materially from those expressed in any forward-looking statements.
0
10
20
30
40
50
60
70
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
Waiting ListOrgans Transplanted
•Parkinson’s ($6 billion/yr)•Stroke ($45 billion/yr)
•Spinal cord injury ($10 billion/yr)•Epilepsy ($3 billion/yr)
•Alzheimer’s ($100 billion/yr)•Multiple sclerosis ($10 billion/yr)
Production of new hES lines that will be safe for
clinical applications
• Feeder-free system• Serum-free system• Elimination of all
animal products, including sialic acids
• Generated using good manufacturing practice (GMP)
A B
C D
E
F
A B
C D
E
F
Generation of ES cells using parthenogenesis
WBC colony from cloned stem cells
•Cardiovascular disease costs the US $329 billion annually
End-stage renal disease will cost US $1 trillion during the coming decade